Legal Representation
Attorney
E. Anthony Figg
USPTO Deadlines
Next Deadline
683 days remaining
Section 8 Declaration Due (Principal Register) (Based on registration date 20211214)
Due Date
December 14, 2027
Grace Period Ends
June 14, 2028
Additional deadlines exist. Contact your attorney for complete deadline information.
Application History
19 events| Date | Code | Type | Description | Documents |
|---|---|---|---|---|
| Nov 21, 2022 | TCCA | I | TEAS CHANGE OF CORRESPONDENCE RECEIVED | Loading... |
| Nov 21, 2022 | ECDR | I | TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS | Loading... |
| Nov 21, 2022 | ARAA | I | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | Loading... |
| Nov 21, 2022 | REAP | I | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | Loading... |
| Dec 14, 2021 | R.PR | A | REGISTERED-PRINCIPAL REGISTER | Loading... |
| Sep 28, 2021 | NPUB | E | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | Loading... |
| Sep 28, 2021 | PUBO | A | PUBLISHED FOR OPPOSITION | Loading... |
| Sep 8, 2021 | NONP | E | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | Loading... |
| Aug 24, 2021 | CNSA | O | APPROVED FOR PUB - PRINCIPAL REGISTER | Loading... |
| Jul 23, 2021 | TEME | I | TEAS/EMAIL CORRESPONDENCE ENTERED | Loading... |
| Jul 23, 2021 | CRFA | I | CORRESPONDENCE RECEIVED IN LAW OFFICE | Loading... |
| Jul 22, 2021 | ALIE | A | ASSIGNED TO LIE | Loading... |
| Jul 8, 2021 | TROA | I | TEAS RESPONSE TO OFFICE ACTION RECEIVED | Loading... |
| Jun 8, 2021 | GNRN | O | NOTIFICATION OF NON-FINAL ACTION E-MAILED | Loading... |
| Jun 8, 2021 | GNRT | F | NON-FINAL ACTION E-MAILED | Loading... |
| Jun 8, 2021 | CNRT | R | NON-FINAL ACTION WRITTEN | Loading... |
| Jun 8, 2021 | DOCK | D | ASSIGNED TO EXAMINER | Loading... |
| Feb 23, 2021 | NWOS | I | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | Loading... |
| Dec 18, 2020 | NWAP | I | NEW APPLICATION ENTERED | Loading... |
Detailed Classifications
Class 042
Scientific and technological services, namely, scientific research, analysis, testing, diagnostic testing in the field of medicine, namely, cancers and autoimmune diseases, and the treatment of illnesses; Pharmaceutical research and development; biomedical research; medical research; scientific chemical and biological laboratory services; scientific laboratory services relating to pharmaceuticals; Development of pharmaceutical products and ingredients; laboratory research and analysis, namely, chemical research and analysis, biological research and analysis; research and design services for the pharmaceutical industry; research and development of new products for others; research into new drugs, namely, pharmaceutical drug development services; research and design services for the pharmaceutical industry; research and development of new products for others; research into new drugs, namely, pharmaceutical drug development services; Scientific research in the field of proteins, antibodies, microorganisms and cells; Scientific research and development in antibody technology; design and development of medical technologies; research and development of antibody conjugates combined with a drug or chemical for the treatment of cancer
First Use Anywhere:
0
First Use in Commerce:
0
Classification
International Classes
042